Posted by Michael Wonder on 27 May 2019
Breast cancer treatments, rare disorders, venlafaxine
27 May 2019 - PHARMAC has published more information on its decisions on the funding of medicines for breast cancer, rare diseases and depression.
In relation to its failure to fund most new medicines for patients with breast cancer, PHARMAC has published a PTAC memorandum from September 2018 that relates to a review of breast cancer. Hardly earth shattering!
